Further experience with the "no-react" bioprosthesis in patients with active infective endocarditis: 11-year single center results in 402 patients.

Objectives  We investigated early, midterm, and long-term results following valve replacement with the “No-React” bioprosthesis in patients with active infective endocarditis (AIE). Patients and Methods  Between February 2000 and February 2011, a total of 402 patients (median 61 years, 17 to 91 years) received “No-React” bioprostheses due to single valve AIE in 315 (aortic valve replacement n  = 158, aortic conduit n  = 30, mitral valve replacement n  = 116, tricuspid valve replacement n  = 11) and double valve AIE in 87 cases. Prosthetic AIE was found in 105 patients (26.1%). Mean follow-up was 2.8 ± 3.2 years (1 month to 11.4 years) with 1,124 patient years, completed in 97.1%. This retrospective study analyzes both prospectively updated data ( n  = 255) and patients recently operated upon ( n  = 147). Results  There was a highly significant difference in the survival between patients operated on urgently and patients operated on in an emergency (30-day, 1-, 5-, and 10-year survival were 80.9 ± 2.3%, 63.8 ± 2.9%, 48.3 ± 3.3%, and 39.7 ± 4.1% vs. 61.3 ± 4.5%, 45.0 ± 4.7%, 33.1 ± 4.6%, and 14.0 ± 5.1%, respectively, p p  = 0.032), single versus double valve replacement ( p  = 0.005), and with or without abscess formation ( p 60 years) and the younger patients. Conclusions  Our experience in the use of “No-React” bioprostheses in patients with native and prosthetic AIE shows satisfactory early, midterm, and long-term results, in particular low rates of reoperation due to recurrent endocarditis and SVD. Because these prostheses are readily available and their implantation straightforward, we strongly recommend their use in patients with AIE. Patients' survival differed significantly depending on their surgical urgency. Early mortality was independently predicted by septic shock, abscess formation, and number of implanted valves besides age per 10 years.